Table 1.
Overview of studies included in the review
| Study no. | References | Therapeutic category | De novo/maintenance therapy | Outcome type | Study population (n) |
|---|---|---|---|---|---|
| 20. | Alessi-Severini et al. [20] | Antipsychotics | M | C | 58 |
| 21. | Amit et al. [21] | Antiarrhythmics | M | C | 114 |
| 22. | Andermann et al. [22] | AED | M | C | 1,354 |
| 23. | Araszkiewicz et al. [23] | Antipsychotics | D | C | 85 |
| 24. | Assawawitoontip and Wiwanitkit [24] | Antihypercholesterolemics (statins) | D | C | 48 |
| 25. | Boh et al. [25] | Antihypercholesterolemics (statins) | D | C | 138 |
| 26. | Burkhardt et al. [26] | AED | M | C | 8 |
| 27. | Carius and Schulze-Bonhage [27] | AED | M | C | 39 |
| 28. | Chaluvadi et al. [28] | AED | M | C | 245 |
| 29. | Diarra et al. [29] | Immunosuppressives | M | C | 59 |
| 30. | Duh et al. [30] | AED | M | E | 1,142 |
| 31. | Duh et al. [31] | AED | M | C + E | 948 |
| 32. | Fujii et al. [32] | Oncology medication (folic acid) | D | C | 42 |
| 33. | Ghate et al. [33] | Anticoagulants | D | C | 37,756 |
| 34. | Halkin et al. [34] | Anticoagulants | M | C | 975 |
| 35. | Halkin et al. [35] | Osteoporosis (bisphosphonates) | D | C | 6,962 |
| 36. | Haroldson et al. [36] | Immunosuppressives | M | C + E | 30 |
| 37. | Hartung et al. [37] | AED | M | C | 616 |
| 38. | Helderman et al. [38] | Immunosuppressives | D | C + E | 227 |
| 39. | Jeong et al. [39] | Anticoagulants | M | C | 20 |
| 40. | Kim et al. [40] | Antihypercholesterolemics (statins) | D | C | 211 |
| 41. | Kluznik et al. [41] | Antipsychotics | M | C | 49 |
| 42. | Labiner et al. [42] | AED | D + M | C | 33,625 |
| 43. | Lai et al. [43] | Osteoporosis (bisphosphonates) | D + M | C | 131 |
| 44. | Layton and Barbeau [44] | Antipsychotics | M | E | 100a |
| 45. | Lee et al. [45] | Anticoagulants | M | C | 35 |
| 46. | LeLorier et al. [46] | AED | M | E | 671 |
| 47. | LeLorier et al. [47] | AED | M | C | 671 |
| 48. | McDevitt-Potter et al. [48] | Immunosuppressives | M | C + E | 70 |
| 49. | Milligan et al. [49] | Anticoagulants | M | C | 182 |
| 50. | Momper et al. [50] | Immunosuppressives | M | C | 103 |
| 51. | Narayanaswamy et al. [51] | Glaucoma medication (prostaglandin analogue) | D | C | 30 |
| 52. | Pamugas et al. [52] | Immunosuppressives | D | C | 60 |
| 53. | Ringe and Moller [53] | Osteoporosis (bisphosphonates) | D | C | 186 |
| 54. | Sajbel et al. [54] | Antipsychotics | M | C | 17 |
| 55. | Ström and Landfeldt [55] | Osteoporosis (bisphosphonates) | D | C | 36,433 |
| 56. | Ude et al. [56] | Antihypertensives | M | C | 221,881 |
| 57. | Van Wijk et al. [57] | Antihypertensives | D | C | 1,028 |
| 58. | Witt et al. [58] | Anticoagulants | M | C + E | 2,299 |
| 59. | Wiwanitkit et al. [59] | Antihypercholesterolemics (statins) | D | C | 43 |
D de novo therapy, M maintenance therapy, D + M both, C clinical, E economic, C + E clinical and economic, AED antiepileptic drug
aPatient number in the health economic decision model